ArticleHealth science reports2026
Trends of Pathogenicity and Potential Risk Evaluation of Central African Mpox Variant to Cause Global Public Health Emergency: A Cross-Sectional Analysis.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: With the re-emergence of monkeypox (Mpox), it is vital for communities to assess and effectively respond to emerging outbreaks. This paper aims to review the potential of clade I Mpox to result in a widespread outbreak by assessing genetically enhanced virulence, transmission, and clinical manifestations. It highlights antiviral therapies, vaccine strategies, and public health initiatives that offer adaptive guidance for policy and management strategies. Methods: A comprehensive literature search written in English was conducted using the PubMed, Scopus, Web of Science, World Health Organization, and the Center for Disease Control and Prevention sources to compile the most up-to-date information on Mpox. Results: The Mpox virus has evolved into two genetically and clinically distinct clades: clade I (Central African) and clade II (West African). Previously, Clade II strains caused a 2022-2023 global outbreak. Genetic mutations in clade I strains have resulted in higher virulence, immune evasion capabilities, and case-fatality rates, causing concern for a future pandemic. To effectively protect against, treat, and contain clade I Mpox, a substantial understanding of its virological, clinical, and epidemiological characteristics is essential. Given the recent history of pandemics, there is much reason to be forward-looking to elicit a more effective response to the next one. Clade I Mpox is better adapted to evade and suppress the human immune response, rendering it more lethal. The similarities to smallpox allow for vaccines tailored for smallpox to be used to prevent Mpox, with good efficacy. Furthermore, some drugs can be used to treat active infections, targeting various components of the Mpox life cycle. Conclusion: Among Mpox clades, clade I is more of a concern as it is more lethal. A solid understanding of the clinical presentation and routes of transmission, measures could be better taken to identify cases and take the proper steps to avoid the spread.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.